New drug YA-101 aims to slow rare brain disease
NCT ID NCT06848231
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests the safety and effectiveness of YA-101, an oral drug, in 75 people with multiple system atrophy (MSA), a rare and progressive brain disorder. Participants will receive either YA-101 or a placebo twice daily for several weeks. The study will monitor side effects and measure drug levels in the blood to see if YA-101 can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YA-101
What this could lead to
If it works, this could point toward a treatment that slows or controls multiple system atrophy, a rare and devastating brain disease.
What could go wrong
This is an early Phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University Irving medical center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-••••
-
Juntendo University Hospital
RECRUITINGTokyo, Japan
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
National Taiwan University Hospital
RECRUITINGTaipei, 100225, Taiwan
Contact Email: •••••@•••••
-
National Taiwan University Hospital Cancer Center
NOT_YET_RECRUITINGTaipei, 106, Taiwan
-
UCLA Health
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-••••
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Email: •••••@•••••